• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Triptolide Alleviates Allergic Rhinitis Inflammation Linked to p38 MAPK Pathway Suppression

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Triptolide Alleviates Allergic Rhinitis Inflammation Linked to p38 MAPK Pathway Suppression

Triptolide Alleviates Allergic Rhinitis Inflammation Linked to p38 MAPK Pathway Suppression

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a newly reported preclinical investigation combining computational modeling with laboratory experiments, researchers found that the natural compound triptolide alleviated key inflammatory features of allergic rhinitis in animal and cellular models, an outcome correlated with the suppression of the p38 mitogen-activated protein kinase signaling pathway. Allergic rhinitis represents a widespread chronic inflammatory disorder of the upper respiratory tract driven largely by exaggerated type 2 helper T cell responses to environmental allergens such as house dust mites, pollen, and animal dander. Clinical manifestations involve recurrent sneezing, nasal rubbing, mucosal thickening, and epithelial barrier dysfunction, often complicated by comorbid allergic conjunctivitis and asthma. Standard medical interventions primarily rely on intranasal corticosteroids, oral antihistamines, and leukotriene receptor antagonists, yet clinical management remains constrained by inadequate therapeutic responses in subsets of individuals, potential long-term adverse events, and the substantial financial costs or pathway-specific limitations of monoclonal biological agents targeting immunoglobulins or epithelial alarmins.

To explore alternative anti-inflammatory strategies capable of engaging complex multi-target regulatory networks, investigators examined triptolide, an epoxidized diterpene lactone derived from the roots of the traditional medicinal plant Tripterygium wilfordii. The investigation began in June 2025 by deploying network pharmacology tools alongside computational molecular docking to map putative therapeutic targets before conducting confirmatory wet-lab assays. The SwissTargetPrediction tool identified 100 candidate target genes associated with triptolide, which were subsequently validated against the UniProt database after filtering out non-human genes, standardizing gene nomenclature, and removing duplicate records. Concurrently, searches across the GeneCards repository utilizing allergic rhinitis and allergy keywords yielded 1,416 disease-relevant targets. Cross-referencing these two datasets through Venny revealed 33 overlapping genes shared between the compound and the disease phenotype, delineating a refined network of candidate targets for subsequent topological analysis.

Constructing a protein-protein interaction network from these 33 shared targets using the STRING database and Cytoscape software demonstrated an interconnected web of 327 edges, wherein degree values and composite scores highlighted major hub nodes. Core interacting targets included interleukin-1 beta, prostaglandin-endoperoxide synthase 2 (also designated cyclooxygenase-2), vascular cell adhesion molecule-1, mitogen-activated protein kinase 14 (also known as p38 alpha), glucocorticoid receptor NR3C1, mitogen-activated protein kinase 8, and NF-kappa-B inhibitor alpha. Functional enrichment profiling conducted via the DAVID platform assigned the shared gene set to biological processes such as cellular responses to lipopolysaccharide, general inflammatory responses, and nuclear receptor-mediated steroid hormone signaling. In parallel, KEGG pathway enrichment flagged 19 statistically significant pathways, most prominently tumor necrosis factor signaling, interleukin-17 signaling, Toll-like receptor signaling, and pathways involved in cellular survival and oncogenesis.

To assess potential structural compatibility between triptolide and predicted core targets, the researchers performed automated molecular docking simulations utilizing PubChem chemical coordinates, Protein Data Bank crystalline structures, PyMOL, and AutoDock Vina. Grid box dimensions were centered on co-crystallized reference ligands with an exhaustiveness parameter established at 20. Docking evaluations for the MAPK14 kinase crystal structure (PDB accession 3gp0) calculated a lowest predicted binding free energy of minus 19.2 kilocalories per mole, well below the minus 5.0 kilocalorie per mole threshold indicative of energetically favorable interactions. Visual analysis suggested that triptolide can position within the hinge region and ATP-binding pocket of MAPK14 via specific hydrogen bonds and hydrophobic contacts. The investigators explicitly emphasized, however, that molecular docking constitutes an in silico prediction and cannot independently prove direct physical binding or pharmacological target engagement in living systems.

The biological activity of triptolide was subsequently evaluated in vivo using specific-pathogen-free female BALB/c mice aged six to eight weeks across randomized cohorts of six animals each. Sensitization was induced by administering intraperitoneal injections of 0.2 milligrams house dust mite extract combined with 100 milligrams aluminum hydroxide adjuvant on experimental days one through eight. From days 15 to 28, mice were challenged every other day through nebulized inhalation of a one percent house dust mite solution for 30 minutes per session. Animals received graded intraperitoneal doses of triptolide at 10, 20, or 30 micrograms per kilogram, while benchmarked cohorts received vehicle alone or dexamethasone at two milligrams per kilogram as an active corticosteroid comparator. Immediately following the final challenge on day 28, allergic symptom severity was quantified by recording the frequencies of nasal rubbing motions and sneezing events during a standardized 10-minute observation window.

Symptom scoring and enzyme-linked immunosorbent assays showed that increasing doses of triptolide significantly alleviated nasal symptoms and reduced serum levels of type 2 inflammatory cytokines, establishing 20 micrograms per kilogram as an optimal moderate intervention dose for extended testing. Histological examination of nasal tissues using hematoxylin and eosin staining demonstrated that sensitized allergic rhinitis model mice developed prominent mucosal thickening, ciliary architecture disruption, and marked inflammatory cell infiltration. Treatment with either 20 micrograms per kilogram of triptolide or two milligrams per kilogram of dexamethasone visibly ameliorated these pathological changes in both nasal mucosa and adjacent lung tissues. Western blot analyses of nasal tissue lysates further revealed that triptolide administration substantially decreased the relative expression of the adhesion molecule VCAM-1 and the pro-inflammatory enzyme PTGS2, paralleled by a marked reduction in phosphorylated p38 MAPK without altering total p38 MAPK protein levels.

To investigate direct cellular responses, human nasal epithelial cells authenticated through short tandem repeat profiling were cultured in vitro and challenged with 200 micrograms per milliliter of house dust mite extract for 48 hours, followed by triptolide exposure for 24 hours. Real-time quantitative polymerase chain reaction assays demonstrated that house dust mite stimulation significantly upregulated mRNA expression of the epithelial-derived alarmins TSLP, IL-25, and IL-33, which serve as upstream drivers of type 2 innate lymphoid responses. Cell counting kit-8 viability testing indicated that house dust mite exposure caused substantial epithelial cytotoxicity, whereas triptolide restored cell viability across concentrations of 5, 10, and 20 micromolar in a manner comparable to dexamethasone. Furthermore, western blotting confirmed that 10 micromolar triptolide significantly attenuated the allergen-induced elevations in VCAM-1, PTGS2, and the ratio of phosphorylated p38 MAPK to total p38 MAPK in cultured epithelial cells.

The mechanistic link between triptolide efficacy and the p38 signaling cascade was verified through chemical pathway intervention assays in cultured human nasal epithelial cells. Cells were treated with the selective p38 MAPK activator Diprovocim or the p38 inhibitor MAPK-IN-1 in the presence or absence of triptolide. When co-administered with triptolide, Diprovocim largely abrogated the protective effects of the natural diterpene, causing a significant rebound in the phosphorylation of p38 MAPK as well as elevated protein levels of PTGS2 and VCAM-1. Conversely, co-treatment with the pharmacological inhibitor MAPK-IN-1 mimicked and enhanced triptolide-mediated anti-inflammatory suppression. Terminal deoxynucleotidyl transferase dUTP nick end labeling immunofluorescence assays further confirmed that house dust mite exposure accelerated epithelial apoptosis, while triptolide protected cells against programmed cell death—an anti-apoptotic benefit reversed by Diprovocim activation and reinforced by MAPK-IN-1 inhibition.

In discussing the physiological relevance of these findings, the authors noted that downregulating p38 MAPK phosphorylation likely reduces the activation of downstream transcription factors such as c-Jun and ATF-2, dampening transcription of PTGS2 and VCAM-1. Decreased PTGS2 curbs the generation of inflammatory lipid mediators that exacerbate vascular permeability and sensory nerve sensitization, while diminished VCAM-1 suppresses vascular adhesion and the subsequent trans-endothelial migration of eosinophils into the nasal mucosa. Additionally, the observed reduction of circulating IL-5, IL-4, IL-13, and total IgE in treated animals directly counters Th2-driven allergic cascades. However, the study highlighted important methodological boundaries: while computational docking predicted stable interaction with MAPK14, direct biochemical binding was not formally proven through biophysical assays such as cellular thermal shift assays, drug affinity responsive target stability, or purified kinase enzymatic assays, nor were genetic knockdown or overexpression rescue experiments performed.

The research team outlined several critical limitations that must temper translation to human medicine. The experimental design lacked hypothalamic-pituitary-adrenal axis measurements, meaning that conclusions regarding potential steroid-sparing capabilities, HPA axis safety, or suitability as an outright replacement for glucocorticoids remain wholly unsupported by the current data. Furthermore, while the compound demonstrated anti-inflammatory efficacy comparable to dexamethasone in this allergen-driven murine model, triptolide carries well-documented risks of clinical hepatotoxicity, reproductive toxicity, and systemic adverse effects. Future translational investigations must incorporate rigorous toxicological monitoring, including serum transaminases, alkaline phosphatase, and liver histopathology, alongside the development of targeted intranasal formulation technologies such as nanoparticles or in situ responsive gels to maximize local respiratory bioavailability while avoiding systemic toxic liabilities.

Subject of Research: Investigation of triptolide mechanisms in allergic rhinitis models

Article Title: Triptolide Ameliorates Allergic Rhinitis and Is Associated With Suppression of the p38 MAPK Pathway: A Network Pharmacology and Experimental Study

Article References: Shi, B., Yang, Q., Wang, F., Song, J., & Bao, Y. (2026). Triptolide Ameliorates Allergic Rhinitis and Is Associated With Suppression of the p38 MAPK Pathway: A Network Pharmacology and Experimental Study. Immunity, Inflammation and Disease, 14(11), Article e70552. https://doi.org/10.1002/iid3.70552

Image Credits: AI Generated

DOI: 10.1002/iid3.70552

Keywords: triptolide, allergic rhinitis, p38 MAPK, MAPK14, house dust mite, HNEpC, BALB/c mice, PTGS2, VCAM1, network pharmacology, molecular docking, dexamethasone, type 2 inflammation, Th2 cytokines, Diprovocim, MAPK-IN-1

News Source: Ophelia Keating. (November 20, 2026). Triptolide Alleviates Allergic Rhinitis Inflammation Linked to p38 MAPK Pathway Suppression. Scienmag.

Tags: allergic rhinitisBALB/c micedexamethasoneDiprovocimHNEpChouse dust miteMAPK-IN-1MAPK14molecular dockingnetwork pharmacologyp38 MAPKPTGS2Th2 cytokinestriptolidetype 2 inflammationVCAM1
Share12Tweet7Share2ShareShareShare1

Related Posts

Wearable Sensors Link Movement Speed Deficits to Diffuse Malignant Parkinson's Disease

Wearable Sensors Link Movement Speed Deficits to Diffuse Malignant Parkinson’s Disease

November 20, 2026
Circadian Syndrome Linked to Higher Risk of Stroke in Arthritis Patients

Circadian Syndrome Linked to Higher Risk of Stroke in Arthritis Patients

November 20, 2026

Faces Pain Scale-Revised Shows Superior Consistency After Glaucoma Goniosynechialysis Surgery

November 20, 2026

Novel PET Tracer Visualizes Periarticular Inflammation in Polymyalgia Rheumatica

November 20, 2026

POPULAR NEWS

  • Metastatic Wilms Tumor Rapidly Develops in Infant With Beckwith–Wiedemann Syndrome

    Metastatic Wilms Tumor Rapidly Develops in Infant With Beckwith–Wiedemann Syndrome

    29 shares
    Share 12 Tweet 7
  • Water Molecules Bridge Spiro Barbiturate Tetrazoles into Stable Macrocyclic Dimers

    29 shares
    Share 12 Tweet 7
  • Gardenia Yellow E500 Shows No Genotoxic or Cell Transformation Effects Across Multi-Tiered Tests

    29 shares
    Share 12 Tweet 7
  • Lower Solution Temperature Degrades High-Temperature Strength and Creep in Ni-Based Superalloy

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Wearable Sensors Link Movement Speed Deficits to Diffuse Malignant Parkinson’s Disease

Circadian Syndrome Linked to Higher Risk of Stroke in Arthritis Patients

Open Source Python Tool CurricuMap Converts University Transcripts into Auditable Competency Matrices

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.